首页 | 本学科首页   官方微博 | 高级检索  
     


Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer
Authors:William L. Dahut  Ravi A. Madan  Joyson J. Karakunnel  David Adelberg  James L. Gulley  Ismail B. Turkbey  Cindy H. Chau  Shawn D. Spencer  Marcia Mulquin  John Wright  Howard L. Parnes  Seth M. Steinberg  Peter L. Choyke  William D. Figg
Affiliation:1. Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, , Bethesda, MD, USA;2. Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, , Bethesda, MD, USA;3. Clinical Pharmacology Program, SAIC‐Frederick, Inc., National Cancer Institute‐Frederick, , Bethesda, MD, USA;4. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, , Bethesda, MD, USA;5. Division of Cancer Prevention, National Cancer Institute, , Bethesda, MD, USA;6. Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, , Bethesda, MD, USA
Abstract:
Keywords:castration‐resistant prostate cancer  angiogenesis inhibitors  cediranib  AZD2171
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号